It is unlikely that cholesterol drug, Vytorin, and related drug, Zetia, raise the risk of cancer. That is the good news for Merck & Co. from the FDA which adds that a link cannot be ruled out until ongoing research is concluded.
Zetia did not do as well in reducing plaque in the artery wall of the neck as the simple B vitamin, niacin, in this published study, which was curtailed early because of the results.
Merck and Schering-Plough agreed on Wednesday to pay $41.5 million to settle class-action lawsuits filed by patients taking the cholesterol drugs Vytorin and Zetia.
Food and Drug Administrators are reviewing data that suggests a higher rate of cancer in patients taking the cholesterol-lowering drug Vytorin. Patients are advised to continue taking Vytorin because the cancer link is unclear at this time.
Our mission is to seek the complete truth and provide a full and fair account of the events and issues that surround personal safety, accident prevention, and injury recovery. We are committed to serving the public with honesty and integrity in these efforts.
On the Road
Major Medical
Protecting Your Family
In the Workplace
Motley Rice Ranked A Best Law Firm by U.S. News and World Report
Tampa Toddler Dies After Being Left In Vehicle
Burn Advocates Network Returns From Mission In Haiti
Update: Burn Advocates Network In Haiti
Burn Advocates Network In Haiti